Email this article REVIEW OF RESULTS OF DOUBLE BLIND PLACEBO-CONTROLLED STUDY OF PHASE III CLADRIBINE IN TABLETS FOR TREATING MULTIPLE SCLEROSIS - CLARITY
- Authors: Sidorenko T.V.1
-
Affiliations:
- Russian State Medical University
- Issue: Vol XLII, No 1 (2010)
- Pages: 75-77
- Section: Articles
- URL: https://journals.rcsi.science/1027-4898/article/view/13584
- DOI: https://doi.org/10.17816/nb13584
- ID: 13584
Cite item
Full Text
Abstract
There was presented a review of foreign publications of 2009 about the investigation results of clinical effectiveness of Cladribine (in tablets) for treating Multiple Sclerosis.
About the authors
Tatyana Valerjevna Sidorenko
Russian State Medical University
Email: t.v.sidorenko@rambler.ru
кафедра неврологии и нейрохирургии лечебного факультета на базе ГКБ №1; Российский государственный медицинский университет; Russian State Medical University
References
- Comi, G. Reduction in MRI activity in relapsing-remitting multiple sclerosis achieved with cladribine tablets in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study / G. Comi, S. Cook, G. Giovannoni et al. //Multiple Sclerosis. - Vol. 15, suppl.2. - S. 136.
- Cook, S. Safety and tolerability of short-course oral treatment with cladribine tablets for relapsing-remitting multiple sclerosis (RRMS) in the 96-week, phase III, double-blind, placebo-controlled CLARITY study / S. Cook, P. Vermersch, G.Comi et al. // Journal of the neurological sciences. - Vol. 285, suppl.1. - S. 206.
- Giovannoni, G. Disease activity-free results for cladribine tablets in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis / G. Giovannoni, G. Comi, S. Cook et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 137.
- Giovanonni G. Clinical outcomes with cladribine tablets in the 96-week, phase III, double-blind, placebo-controlled CLARITY study in patients with relapsing-remitting multiple sclerosis / G. Giovanonni, G. Comi, S. Cook et.al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 136-137.
- Leist, T.P. Mode of action (MoA) of cladribine tablets: activity in lymphocytes and implications for treatment of multiple sclerosis (MS) / T.P. Leist, M. Migliaccio, R. Weissert. // Journal of the neurological sciences. - Vol. 285, suppl.1. - S. 206-207.
- Miret, M. Evaluation of the long -term safety of cladribine tablets: design of a prospective 8-year safety registry / M. Miret, L. Perez-Gutthann, V. Viglietta et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 239.
- Soelberg-Sшrensen, P. Effect of cladribine tablets on haematological profiles in patients with relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study / P. Soelberg-Sшrensen, G. Comi, S. Cook et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 137.
- Vermersch, P. Early onset of effects of treatment with cladribine tablets for relapsing-remitting multiple sclerosis in the 96-week, Phase III, double-blind, placebo-controlled CLARITY study / P. Vermersch, G. Comi, S. Cook et al. // Multiple Sclerosis. - Vol. 15, suppl. 2. - S. 249.
- Viglietta, V. Clinical development plan for cladribine tablets, an oral immunomodulator, for the treatment of multiple sclerosis / V. Viglietta, S. Greenberg, D. Mikol et al. // Multiple Sclerosis. Vol. 15, suppl. 2. - S. 126-127.
Supplementary files
